AFFiRiS

Executive Summary

AFFiRiS is a clinical-stage biopharmaceutical company based in Vienna, Austria, focused on developing Specific Active Immunotherapies (SAIT) for chronic diseases, particularly neurodegenerative conditions and hypercholesterolemia. Leveraging its proprietary AFFITOME® platform, the company aims to stimulate the immune system to target disease-associated proteins. AFFiRiS has advanced a pipeline of vaccine candidates into Phase 1 trials, targeting Alzheimer's disease, Parkinson's disease, and atherosclerosis. With a strong intellectual property portfolio and a differentiated approach that offers potential for disease-modifying effects, AFFiRiS represents a promising biotech investment opportunity. However, the company remains private and early-stage, with no disclosed funding rounds or valuation, which increases risk. Key upcoming catalysts include initial clinical data readouts and potential strategic partnerships to advance its platform.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for Alzheimer's vaccine candidate AD0240% success
• Q4 2026Initiation of Phase 1/2 trial for Parkinson's vaccine candidate PD01A50% success
• TBDAnnouncement of strategic partnership or licensing deal for AFFITOME platform35% success